Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

NCT01408732 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT01408732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01408732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Lead sponsor
University of Minnesota
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2011
Completion date
September 30, 2014
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epistaxis, hereditary hemorrhagic telangiectasia